A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting 94 enrolled BeOne Medicines

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.

Timeline

Start: 2024-11-14
Primary completion: 2026-11
Completion: 2029-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sonrotoclax	Other / unclassified	—	Oral
Subject	Zanubrutinib	Small molecule	—	Oral

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications